Evaluating Treatment Success in CGRP Antibody Prophylaxis: A Retrospective Cohort Study Comparing Monthly Migraine Days, MIDAS Scores, and HIT-6 Scores
Abstract
Monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) or its receptor represent a major advance in migraine prevention. However, standardized criteria for assessing treatment response are lacking. This study aimed to compare responder rates based on monthly migraine days (MMDs), the Migraine Disability Assessment (MIDAS), and the Headache Impact Test (HIT-6), and to evaluate whether a single outcome measure may be sufficient for therapeutic decision-making. In this retrospective, single-center study, 417 patients with episodic or chronic migraine treated with a CGRP or CGRP receptor monoclonal antibody between January 2020 and June 2023 were analyzed. Inclusion required complete documentation of MMDs, MIDAS scores, and HIT-6 scores. Response was defined as a ≥ 50% (episodic) or ≥ 30% (chronic) MMDs reduction, a ≥ 30% MIDAS reduction (baseline > 20), and/or a ≥ 5-point HIT-6 improvement. In episodic migraine, 50.3% of patients met the MMDs response criterion, while 69.5% and 67.5% responded as per MIDAS and HIT-6, respectively. In chronic migraine, the response rates were 58.2% (MMDs), 48.2% (MIDAS), and 55.0% (HIT-6). Combining all three parameters identified treatment response in 84.8% of episodic and 77.7% of patients with chronic migraine. Only 1.5% of patients with episodic migraine would have been misclassified as non-responders if solely PROMs were used. Treatment discontinuation due to adverse events occurred in 3.3% of patients. Outcome measures…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 417 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.